IMIDomics discovers and develops precision medicines using our Precision Discovery Engine. This proprietary data-powered system integrates clinical, epidemiologic and multi-omic biomolecular data, to identify new targets or new applications for existing compounds, based on precisely defined patient populations.
Patients with IMIDs need treatment options that offer better health outcomes and an improved quality of life. We know that better and more effective precision treatments for IMIDs are possible and understand this can only be achieved through detailed, precise information from diagnosed IMID patients. Our deep understanding of IMIDs is enabled by over 15 years of patient data and sample collection, giving IMIDomics a unique edge in generating clinical insights about IMIDs.
Total Funding: $16.5 M
Funding Stage: Series A
Business Stage: N/A
Market: B2C
Company Size: 1 to 25
Founded: 2019
Oct 2021
- IMIDomics Sponsors the Online Symposium
Jul 2021
- IMIDomics Co-organizes Symposium
Oct 2020
- Drug9 Identifie Candidate for Severe COVID-1d by IMIDomics and VHIR Rheumatology Group
Feb 2020
- IMIDomics and Gossamer Bio Enter into a Strategic Collaboration
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at IMIDomics
Machine Learning Specialist
Barcelona, Remote
Bioinformatics Scientist
Barcelona, Remote
